Buscar
Mostrando ítems 1-6 de 6
Artículo
Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy
(Amer Publ Co, 2019)
Background: Immune escape of tumor cells is a new hallmark of cancer in general, and breast cancer, in particular. Previous studies have demonstrated that the immunological profile in peripheral blood may be a prognostic ...
Artículo
Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells
(Mdpi Ag, 2023)
Breast cancer (BC) continues to be the most diagnosed tumor in women and a very heterogeneous disease both inter- and intratumoral, mainly given by the variety of molecular profiles with different biological and clinical ...
Artículo
Obesity and Breast Cancer: Role of Leptin
(2019-07-18)
Obesity-related breast cancer is an important threat that affects especially post-menopausal women. The link between obesity and breast cancer seems to be relying on the microenvironment generated at adipose tissue level, ...
Artículo
Sam68 Mediates the Activation of Insulin and Leptin Signalling in Breast Cancer Cells
(Public Library Science, 2016)
Obesity is a well-known risk factor for breast cancer development in postmenopausal women. High insulin and leptin levels seem to have a role modulating the growth of these tumours. Sam68 is an RNA-binding protein with ...
Artículo
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
(Nature publishing group, 2021)
Identifcation of the diferent elements intervening at the tumor microenvironment seems key to explain clinical evolution in several tumor types. In this study, a set of immune biomarkers (myeloid derived suppressor ...
Artículo
Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
(MDPI, 2021-10-29)
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative advanced breast cancer patients. Treatment consisted of 21-day cycles ...